Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Universitair Medisch Centrum Utrecht
Sponsor

Universitair Medisch Centrum Utrecht

The Netherlands Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

About the sponsor

Universitair Medisch Centrum Utrecht is active in studies across solid tumors and blood cancers, with interest in colorectal cancer, head and neck squamous cell carcinoma, endometrial cancer, liver metastases, acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Its trial portfolio also includes rare and difficult-to-treat cancers such as parotid gland carcinoma, diffuse midline glioma, and pheochromocytoma.

  • metastatic colorectal cancer
  • oral cancer
  • colorectal liver metastases
  • H3K27-altered pontine diffuse midline glioma
  • acute myeloid leukemia

Research interests extend to sentinel lymph node mapping, imaging-guided treatment selection, and locoregional approaches for advanced malignancy.

About Specializations

Universitair Medisch Centrum Utrecht runs clinical trials in conditions such as Brain injury, Dermatomyositis, Antisynthetase syndrome, Behcet's syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

47 clinical trials

Hepatic cancer

Recruiting

Study of intra-arterial angiotensin II during radioembolization to improve treatment effectiveness in patients with primary or secondary liver cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Angiotensin II
  • Sponsor:Universitair Medisch Centrum Utrecht

Post-acute COVID-19 syndrome

Recruiting

Study on Metformin and Colchicine for Patients with Long COVID Symptoms

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitair Medisch Centrum Utrecht

ROHHAD syndrome

Recruiting

Study on Setmelanotide for Improving Hypothalamic Function in Patients with ROHHAD Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Setmelanotide
  • Sponsor:Universitair Medisch Centrum Utrecht

Peripheral artery restenosis+4

Recruiting

Study on the Effect of Clopidogrel and Acetylsalicylic Acid on Reducing Heart and Blood Vessel Events in Patients with Peripheral Arterial Disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Universitair Medisch Centrum Utrecht

Heart disease congenital+1

Recruiting

Study on Allopurinol Sodium for Brain Injury Prevention in Newborns with Critical Congenital Heart Disease Undergoing Heart Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Epilepsy

Recruiting

Study on Cannabidiol and Dronabinol for Children with Refractory Epilepsy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Universitair Medisch Centrum Utrecht

Ischaemic stroke

Recruiting

Study on Darbepoetin Alfa for Reducing Brain Injury in Newborns with Perinatal Arterial Ischemic Stroke

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Darbepoetin Alfa
  • Sponsor:Universitair Medisch Centrum Utrecht

Intracranial calcification

Recruiting

Study on the Effects of Etidronate on Brain Calcification in Patients with Fahr's Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etidronate Disodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Factor VIII deficiency

Recruiting

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Universitair Medisch Centrum Utrecht

Salivary gland cancer

Recruiting

Study on Sentinel Lymph Node Biopsy for Parotid Gland Cancer Using Gallium (68Ga) Chloride and Tilmanocept in Patients Undergoing Parotidectomy and Neck Dissection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tilmanocept
  • Sponsor:Universitair Medisch Centrum Utrecht

Anti-myelin-associated glycoprotein associated polyneuropathy

Recruiting

Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.